| ［1］ |
Dummer R, Vermeer MH, Scarisbrick JJ, et al. Cutaneous T cell lymphoma［J］. Nat Rev Dis Primers, 2021,7（1）:61. doi: 10.1038/ s41572-021-00296-9.
|
| ［2］ |
Wright A, Wijeratne A, Hung T, et al. Prevalence and severity of pruritus and quality of life in patients with cutaneous T-cell lymphoma［J］. J Pain Symptom Manage, 2013,45（1）:114-119. doi: 10.1016/j.jpainsymman.2012.01.012.
|
| ［3］ |
Vij A, Duvic M. Prevalence and severity of pruritus in cutaneous T cell lymphoma［J］. Int J Dermatol, 2012,51（8）:930-934. doi: 10.1111/j.1365-4632.2011.05188.x.
|
| ［4］ |
Ottevanger R, Van Beugen S, Evers AWM, et al. Quality of life in patients with mycosis fungoides and Sézary syndrome: a systematic review of the literature［J］. J Eur Acad Dermatol Venereol, 2021,35（12）:2377-2387. doi: 10.1111/jdv.17570.
|
| ［5］ |
Schmelz M, Schmidt R, Bickel A, et al. Specific C-receptors for itch in human skin［J］. J Neurosci, 1997,17（20）:8003-8008. doi: 10.1523/jneurosci.17-20-08003.1997.
|
| ［6］ |
Handwerker HO. Microneurography of pruritus［J］. Neurosci Lett, 2010,470（3）:193-196. doi: 10.1016/j.neulet.2009.06.092.
|
| ［7］ |
Yosipovitch G, Rosen JD, Hashimoto T. Itch: from mechanism to （novel） therapeutic approaches［J］. J Allergy Clin Immunol, 2018,142（5）:1375-1390. doi: 10.1016/j.jaci.2018.09.005.
|
| ［8］ |
Wilzopolski J, Kietzmann M, Mishra SK, et al. TRPV1 and TRPA1 channels are both involved downstream of histamine-induced itch［J］. Biomolecules, 2021,11（8）:1166. doi: 10.3390/biom11081166.
|
| ［9］ |
Wilson SR, Gerhold KA, Bifolck-Fisher A, et al. TRPA1 is required for histamine-independent, Mas-related G protein-coupled receptor-mediated itch［J］. Nat Neurosci, 2011,14（5）:595-602. doi: 10.1038/nn.2789.
|
| ［10］ |
Wang F, Yang T-L B, Kim BS. The Return of the mast cell: new roles in neuroimmune itch biology［J］. J Invest Dermatol, 2020,140（5）:945-951. doi: 10.1016/j.jid.2019.12.011.
|
| ［11］ |
Rabenhorst A, Schlaak M, Heukamp LC, et al. Mast cells play a protumorigenic role in primary cutaneous lymphoma［J］. Blood, 2012,120（10）:2042-2054. doi: 10.1182/blood-2012-03-415638.
|
| ［12］ |
Shimizu K, Andoh T, Makino T, et al. Mechanisms of itching in mycosis fungoides: grade of itching correlates with eosinophil infiltration and kallikrein 5 expression［J］. Eur J Dermatol, 2019,29（3）:268-273. doi: 10.1684/ejd.2019.3560.
|
| ［13］ |
Ionescu MA, Rivet J, Daneshpouy M, et al. In situ eosinophil activation in 26 primary cutaneous T-cell lymphomas with blood eosinophilia ［J］. J Am Acad Dermatol, 2005,52（1）:32-39. doi: 10.1016/j.jaad.2004.03.003.
|
| ［14］ |
Tancrede-Bohin E, Ionescu MA, De La Salmoniere P, et al. Prognostic value of blood eosinophilia in primary cutaneous T-cell lymphomas［J］. Arch Dermatol, 2004,140（9）:1057-1061. doi: 10.1001/archderm.140.9.1057.
|
| ［15］ |
Durgin JS, Weiner DM, Wysocka M, et al. The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: pathways and targets for immune restoration and tumor eradication［J］. J Am Acad Dermatol, 2021,84（3）:587-595. doi: 10.1016/j.jaad.2020.12.027.
|
| ［16］ |
Tsianakas A, Stander S. Dupilumab: a milestone in the treatment of atopic dermatitis［J］. Lancet, 2016,387（10013）:4-5. doi: 10. 1016/S0140-6736（15）00389-X.
|
| ［17］ |
Steck O, Bertschi NL, Luther F, et al. Rapid and sustained control of itch and reduction in Th2 bias by dupilumab in a patient with Sezary syndrome［J］. J Eur Acad Dermatol Venereol, 2021,35（6）:1331-1337. doi: 10.1111/jdv.17001.
|
| ［18］ |
Espinosa ML, Nguyen MT, Aguirre AS, et al. Progression of cutaneous T-cell lymphoma after dupilumab: case review of 7 patients［J］. J Am Acad Dermatol, 2020,83（1）:197-199. doi: 10.1016/j.jaad.2020.03.050.
|
| ［19］ |
Hollins LC, Wirth P, Fulchiero GJ, Jr., et al. Long-standing dermatitis treated with dupilumab with subsequent progression to cutaneous T-cell lymphoma［J］. Cutis, 2020,106（2）:E8-E11. doi: 10.12788/cutis.0074.
|
| ［20］ |
Datsi A, Steinhoff M, Ahmad F, et al. Interleukin-31: the "itchy" cytokine in inflammation and therapy［J］. Allergy, 2021,76（10）:2982-2997. doi: 10.1111/all.14791.
|
| ［21］ |
Nattkemper LA, Martinez-Escala ME, Gelman AB, et al. Cutaneous T-cell lymphoma and pruritus: the expression of IL-31 and its receptors in the skin［J］. Acta Derm Venereol, 2016,96（7）:894-898. doi: 10.2340/00015555-2417.
|
| ［22］ |
Abreu M, Miranda M, Castro M, et al. IL-31 and IL-8 in Cutaneous T-Cell lymphoma: looking for their role in itch［J］. Adv Hematol, 2021,2021:5582581. doi: 10.1155/2021/5582581.
|
| ［23］ |
Singer EM, Shin DB, Nattkemper LA, et al. IL-31 is produced by the malignant T-cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus［J］. J Invest Dermatol, 2013,133（12）:2783-2785. doi: 10.1038/jid.2013.227.
|
| ［24］ |
Cedeno-Laurent F, Singer EM, Wysocka M, et al. Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities［J］. Clin Immunol, 2015,158（1）:1-7. doi: 10.1016/j.clim.2015.02.014.
|
| ［25］ |
Skoff A M, Adler J E. Nerve growth factor regulates substance P in adult sensory neurons through both TrkA and p75 receptors［J］. Exp Neurol, 2006,197（2）:430-436. doi: 10.1016/j.expneurol. 2005.10.006.
|
| ［26］ |
Suga H, Sugaya M, Miyagaki T, et al. Association of nerve growth factor, chemokine （C-C motif） ligands and immunoglobulin E with pruritus in cutaneous T-cell lymphoma［J］. Acta Derm Venereol, 2013,93（2）:144-149. doi: 10.2340/00015555-1428.
|
| ［27］ |
Azimi E, Reddy VB, Pereira PJS, et al. Substance P activates Mas-related G protein-coupled receptors to induce itch［J］. J Allergy Clin Immunol, 2017,140（2）:447-453 e3. doi: 10.1016/j.jaci.2016.12.980.
|
| ［28］ |
Alam M, Buddenkotte J, Ahmad F, et al. Neurokinin 1 receptor antagonists for pruritus［J］. Drugs, 2021,81（6）:621-634. doi: 10.1007/s40265-021-01478-1.
|
| ［29］ |
Maronas-Jimenez L, Estrach T, Gallardo F, et al. Aprepitant improves refractory pruritus in primary cutaneous T-cell lymphomas: experience of the Spanish Working Group on Cutaneous Lymphomas［J］. Br J Dermatol, 2018,178（4）:e273-e4. doi: 10.1111/bjd.16128.
|
| ［30］ |
Zic J A, Straka B T, Mcgirt L Y, et al. Aprepitant for the treatment of pruritus in Sezary syndrome: a randomized crossover clinical trial［J］. JAMA Dermatol, 2018,154（10）:1221-1222. doi: 10.1001/jamadermatol.2018.2510.
|
| ［31］ |
Steinhoff M, Neisius U, Ikoma A, et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin［J］. J Neurosci, 2003,23（15）:6176-6180. doi: 10.1523/jneurosci.23-15-06176.2003.
|
| ［32］ |
Sakamoto M, Miyagaki T, Kamijo H, et al. Serum vascular endothelial growth factor A levels reflect itch severity in mycosis fungoides and Sézary syndrome［J］. J Dermatol, 2018,45（1）:95-99. doi: 10.1111/1346-8138.14033.
|
| ［33］ |
Chen Z-F. A neuropeptide code for itch［J］. Nat Rev Neurosci, 2021,22（12）:758-776. doi: 10.1038/s41583-021-00526-9.
|
| ［34］ |
Corder G, Castro DC, Bruchas MR, et al. Endogenous and exogenous opioids in pain［J］. Annu Rev Neurosci, 2018,41:453-473. doi: 10.1146/annurev-neuro-080317-061522.
|
| ［35］ |
Phan NQ, Bernhard JD, Luger TA, et al. Antipruritic treatment with systemic mu-opioid receptor antagonists: a review［J］. J Am Acad Dermatol, 2010,63（4）:680-688. doi: 10.1016/j.jaad.2009. 08.052.
|
| ［36］ |
Wang Z, Jiang C, Yao H, et al. Central opioid receptors mediate morphine-induced itch and chronic itch via disinhibition［J］. Brain, 2021,144（2）:665-681. doi: 10.1093/brain/awaa430.
|
